- A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s
-
Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion inj
- Subasinghe, Nalin L.,Travins, Jeremy M.,Ali, Farah,Huang, Hui,Ballentine, Shelley K.,Marugan, Juan Jose,Khalil, Ehab,Hufnagel, Heather R.,Bone, Roger F.,Desjarlais, Renee L.,Crysler, Carl S.,Ninan, Nisha,Cummings, Maxwell D.,Molloy, Christopher J.,Tomczuk, Bruce E.
-
p. 2200 - 2204
(2007/10/03)
-
- Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
-
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
- -
-
-
- NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
-
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
- -
-
Page 352-353
(2010/02/05)
-